azelastine intranasal / Generic mfg. - LARVOL DELTA

Bridging the Pediatric Evidence Gap for Viral Prophylaxis With Intranasal Azelastine (AAO-HNSF 2026) - "In this large national pediatric cohort, intranasal Azelastine was associated with reduced short-term incidence of multiple viral respiratory infections. These findings reinforce earlier pediatric clinical observations and align with emerging adult data, supporting the potential role of Azelastine as an adjunctive preventive strategy in children."

Clinical • Allergic Rhinitis • Immunology • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Real-world effectiveness of fluticasone propionate-azelastine nasal spray in moderate-to-severe nonallergic and perennial allergic rhinitis. (PubMed, World Allergy Organ J) - "The effectiveness of FP-Aze in moderate-to-severe NAR was noninferior to PAR on the VAS for rhinitis, supporting its use in this population. These findings help address an important evidence gap, as data supporting FP-Aze in NAR remain limited."

Journal • Real-world evidence • Allergic Rhinitis • Immunology • Inflammation

Azelastine-Fluticasone Intranasal Combination Therapy in Otorhinolaryngology: Clinical Evidence, Current Practice Patterns and Future Perspectives. (PubMed, Clin Otolaryngol) - "Azelastine-fluticasone combination therapy represents an evidence-based, guideline-recommended option for moderate-to-severe AR in ENT practice. Its dual mechanism, rapid onset, favourable safety profile and high patient acceptability support its integration into contemporary treatment algorithms, particularly for patients requiring enhanced symptom control beyond monotherapy. The combination represents a meaningful therapeutic advancement, and further research is needed to fully characterise its role in perennial AR management."

Journal • Allergic Rhinitis • Immunology • Inflammation • Otorhinolaryngology

Effects of intranasal antihistaminic and corticosteroid therapies on olfactory dysfunction in adults with perennial allergic rhinitis: a prospective comparative study. (PubMed, Eur Arch Otorhinolaryngol) - "In adults with perennial allergic rhinitis and objectively confirmed hyposmia, intranasal corticosteroid-containing regimens were associated with greater improvement in olfactory function than azelastine monotherapy. These findings suggest that intranasal corticosteroid-containing regimens may be preferable when olfactory dysfunction accompanies perennial allergic rhinitis. However, given the non-randomized and open-label design of the study, the results should be interpreted with caution."

Journal • Allergic Rhinitis • Immunology • Inflammation

Intranasal Azelastine for Recurrent Acute Rhinosinusitis Prophylaxis: A Multicenter Retrospective Study. (PubMed, Int Forum Allergy Rhinol) - "Treatment effect consistent across subgroups, from patients using intranasal corticosteroids (ICS) to those with concurrent chronicc rhinosinusitis (CRS). Findings support prospective randomized controlled trial evaluation of azelastine for recurrent acute rhinosinusitis (RARS)."

Journal • Retrospective data • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Open-Label Clinical Trial To Evaluate The Effect Of Intranasal Olopatadine/Mometasone And Azelastine/Mometasone On Histamine Reactivity In Skin Prick Tests (EAACI 2026) - "Conclusion Intranasal antihistamines exert a measurable suppressive effect on histamine-induced skin and sensory responses that persists beyond the dosing period. A washout interval of approximately five days is recommended before performing skin testing in patients treated with intranasal azelastine or olopatadine"

Clinical • Allergic Rhinitis • Allergy • Immunology • Inflammation

Efficacy and Adherence of Combined Fluticasone Propionate and Azelastine Nasal Spray Versus Fluticasone Propionate Alone in Pediatric Allergic Rhinitis. (PubMed, Allergy Asthma Immunol Res) - "AzeFlu therapy may be preferred in patients with persistent symptoms and unresponsive to other treatments. Especially in adolescent children with persistent AR, AzeFlu should be considered as first-line treatment to increase treatment adherence."

Journal • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Azelastine reduces ARS episodes in RARS patients: A retrospective cohort study (COSM 2026) - "Conclusion Azelastine nasal spray was associated with significant ARS episode reduction in RARS patients. These findings support azelastine's potential as prophylactic therapy and warrant prospective controlled trial validation."

Retrospective data • Allergic Rhinitis • Asthma • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Early Endoscopic Closure as a New Paradigm for Traumatic Skull Base Dural Injury (COSM 2026) - "Conclusion Azelastine nasal spray was associated with significant ARS episode reduction in RARS patients. These findings support azelastine's potential as prophylactic therapy and warrant prospective controlled trial validation."

Allergic Rhinitis • Asthma • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Otorhinolaryngology • Respiratory Diseases • Sinusitis

INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION (clinicaltrials.gov) - P4 | N=61 | Active, not recruiting | Sponsor: Pamukkale University

New P4 trial • Allergic Rhinitis • Immunology • Inflammation

Azelastine-Fluticasone Combination Therapy in Allergic Rhinitis: Current Evidence and Clinical Implications in Children and Adults. (PubMed, Pharmaceuticals (Basel)) - "While a combination intranasal spray of azelastine hydrochloride and fluticasone propionate (Aze-Flu) is an established effective treatment for adults with moderate-to-severe AR, the clinical evidence available in the pediatric population is limited. The available evidence supports Aze-Flu as an effective and well-tolerated therapeutic option for children with moderate-to-severe AR, offering superior and faster symptom control than monotherapy and leading to meaningful improvements in quality of life. Future pediatric trials should incorporate validated, child-specific assessment tools to better capture treatment efficacy."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation • Pediatrics • Respiratory Diseases

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection (clinicaltrials.gov) - P4 | N=280 | Recruiting | Sponsor: University of Chicago | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nasal saline irrigation with azelastine-fluticasone nasal spray in moderate-to-severe persistent allergic rhinitis: a randomized controlled trial. (PubMed, Front Allergy) - "The experimental group received nasal saline irrigation combined with azelastine-fluticasone (Aze-Flu) nasal spray, and the control group was treated with azelastine nasal spray and fluticasone nasal spray. This combination therapy could be a valuable option in primary care settings. http://www.medicalresearch.org.cn, identifier (MR-32-23-044661)."

Clinical • Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Acquired Post-Infectious Silent Sinus Syndrome in a Pediatric Patient (AAO-HNSF 2025) - "The patient was successfully treated with medical management and subsequently underwent an adenoidectomy two months later.Despite treatment with maintenance Flonase and Astepro, she continued to experience recurrent sinusitis over the following 1.75 years... This case highlights a rare instance of acquired post-infectious silent sinus syndrome in a pediatric patient, demonstrating the condition's progression over two years. Radiographic images will enhance the presentation of the natural perioperative progression. The planned right maxillary antrostomy aims to address maxillary sinus patency, with post-operative outcomes to be shared at an upcoming conference, pending abstract acceptance."

Clinical • Dermatology • Novel Coronavirus Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Pediatrics • Respiratory Diseases • Septic Shock • Sinusitis

Late Breaking Abstract - The important role of allergic rhinitis treatment in pediatric asthma (ERS 2025) - "Three-week treatment with intranasal azelastine/fluticasone significantly reduces EIB severity in children with asthma and AR. These findings support the important role of upper airway treatment in pediatric asthma management."

Clinical • Late-breaking abstract • Allergic Rhinitis • Asthma • Immunology • Inflammation • Pediatrics • Respiratory Diseases

Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial. (PubMed, JAMA Intern Med) - "These findings support the potential of azelastine as a safe prophylactic approach warranting confirmation in larger, multicentric trials. EudraCT number: 2022-003756-13."

Clinical • Journal • P2 data • Allergic Rhinitis • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparison table: Some nasal sprays for seasonal allergic rhinitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation

Comparative Pharmacokinetic and Tolerability Review of Over-the-Counter and Prescription Azelastine Hydrochloride for Allergic Rhinitis Management (AAAAI-WAO 2025) - "Conclusions The OTC switch to Astepro® 0.15% offers enhanced flexibility in dosing, 50% higher azelastine HCl concentration, and a novel bitterness taste masking technology. This formulation ensures greater systemic exposure with a similar safety profile compared to the prescription formulations, offering a promising solution for AR sufferers."

PK/PD data • Review • Allergic Rhinitis • Immunology • Inflammation

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection (clinicaltrials.gov) - P4 | N=280 | Recruiting | Sponsor: University of Chicago | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis (clinicaltrials.gov) - P4 | N=22 | Completed | Sponsor: University of Chicago | Unknown status ➔ Completed

Trial completion • Allergic Rhinitis • Immunology • Inflammation

Onset-of-Efficacy of Azelastine HCl 0.15% Nasal Spray for allergic rhinitis in an environmental exposure chamber. (PubMed, Ann Allergy Asthma Immunol) - "Azelastine HCl 0.15% nasal spray relieves nasal symptoms associated with allergic rhinitis and has a fast onset of action within 30 minutes. The overall safety profile of azelastine has also been proven to be safe. These results, along with prior findings on efficacy and improved quality of life for people suffering from allergic rhinitis, establish the important clinical role of azelastine HCl 0.15%."

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Chronic rhinosinusitis with nasal polyposis: an old problem with a new solution (EAACI 2024) - "Case report: 40-year-old male with CRSwNP, asthma and acetylsalicylic acid hypersensitivity, followed up by Otorhinolaryngology and Immunoallergology. Since adolescence, he described persistent nasal obstruction, rhinorrhea and anosmia, with significant impact on quality of life, treated with desloratadine 5mg id, montelukast 10mg id, mometasone nasal spray 50mcg bid, and formoterol+budesonide 160+4,5mcg bid...Despite medical treatment adjustment with ebastine 10mg id, budesonide nasal spray 100mcg bid and association of azelastine nasal spray 1mg/ml id, there was no significant improvement and multiple cycles of systemic corticosteroids were prescribed due to acute exacerbations... In this patient, treatment with dupilumab has translated into a substantial improvement of all the evaluated parameters. The advent of biological therapeutics offers new approaches for medical practitioners and hope for CRSwNP patients."

Immunology • IL4

Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis (clinicaltrials.gov) - P4 | N=150 | Recruiting | Sponsor: Zheng Liu ENT | Trial completion date: Jul 2024 ➔ Jan 2025 | Trial primary completion date: May 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Allergic Rhinitis • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation

The impact of nasal use of azelastine and mometasone furoate on drug-induced sleep endoscopy. (PubMed, Eur Rev Med Pharmacol Sci) - "This study first investigated nasal mometasone furoate and azelastine on DISE. This study showed that prior use of nasal mometasone furoate or azelastine before DISE did not affect the amount of secretion, tolerance level, severity, and configuration of obstruction."

Journal